These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20423340)

  • 1. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.
    Ludolph AG; Udvardi PT; Schaz U; Henes C; Adolph O; Weigt HU; Fegert JM; Boeckers TM; Föhr KJ
    Br J Pharmacol; 2010 May; 160(2):283-91. PubMed ID: 20423340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
    Udvardi PT; Föhr KJ; Henes C; Liebau S; Dreyhaupt J; Boeckers TM; Ludolph AG
    Drug Des Devel Ther; 2013; 7():1433-46. PubMed ID: 24348020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.
    Scherer D; Hassel D; Bloehs R; Zitron E; von Löwenstern K; Seyler C; Thomas D; Konrad F; Bürgers HF; Seemann G; Rottbauer W; Katus HA; Karle CA; Scholz EP
    Br J Pharmacol; 2009 Jan; 156(2):226-36. PubMed ID: 19154426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants.
    Thomason C; Michelson D
    Drugs Today (Barc); 2004 May; 40(5):465-73. PubMed ID: 15319800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.
    Tzavara ET; Bymaster FP; Overshiner CD; Davis RJ; Perry KW; Wolff M; McKinzie DL; Witkin JM; Nomikos GG
    Mol Psychiatry; 2006 Feb; 11(2):187-95. PubMed ID: 16231039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex.
    Sun H; Cocker PJ; Zeeb FD; Winstanley CA
    Psychopharmacology (Berl); 2012 Jan; 219(2):285-301. PubMed ID: 21809008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
    Bakken RJ; Paczkowski M; Kramer HP; Axelson AA; Williams DW; Malcolm SK; Sumner CR; Kelsey DK
    Curr Med Res Opin; 2008 Feb; 24(2):449-60. PubMed ID: 18179733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
    Dell'Agnello G; Zuddas A; Masi G; Curatolo P; Besana D; Rossi A
    CNS Drugs; 2009 Sep; 23(9):739-53. PubMed ID: 19689165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
    Ruocco LA; Carnevale UA; Treno C; Sadile AG; Melisi D; Arra C; Ibba M; Schirru C; Carboni E
    Behav Brain Res; 2010 Jun; 210(1):99-106. PubMed ID: 20156489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine.
    Redding ZV; Sabol KE
    J Psychopharmacol; 2023 Feb; 37(2):204-215. PubMed ID: 36648101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.
    Newman LA; Darling J; McGaughy J
    Psychopharmacology (Berl); 2008 Sep; 200(1):39-50. PubMed ID: 18568443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atomoxetine on attention and impulsivity in the five-choice serial reaction time task in rats with lesions of dorsal noradrenergic ascending bundle.
    Liu YP; Huang TS; Tung CS; Lin CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():81-90. PubMed ID: 25151304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
    Husarova V; Bittsansky M; Ondrejka I; Dobrota D
    Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics.
    Barygin OI; Nagaeva EI; Tikhonov DB; Belinskaya DA; Vanchakova NP; Shestakova NN
    Brain Res; 2017 Apr; 1660():58-66. PubMed ID: 28167075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.